| Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in NeuroblastomaCDK4/6 Inhibition in Neuroblastoma JA Rader, MR Russell, LS Hart, MS Nakazawa, LT Belcastro, D Martinez, ... Clinical cancer research 19 (22), 6173-6182, 2013 | 342 | 2013 |
| RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma KA Cole, J Huggins, M Laquaglia, CE Hulderman, MR Russell, K Bosse, ... Proceedings of the National Academy of Sciences 108 (8), 3336-3341, 2011 | 253 | 2011 |
| CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility LocusCASC15 Is a Neuroblastoma Suppressor Gene MR Russell, A Penikis, DA Oldridge, JR Alvarez-Dominguez, L McDaniel, ... Cancer research 75 (15), 3155-3166, 2015 | 134 | 2015 |
| Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in NeuroblastomaDual Inhibition of Chk1/Wee1 in Neuroblastoma MR Russell, K Levin, JA Rader, L Belcastro, Y Li, D Martinez, B Pawel, ... Cancer research 73 (2), 776-784, 2013 | 127 | 2013 |
| Rare Variants in TP53 and Susceptibility to Neuroblastoma SJ Diskin, M Capasso, M Diamond, DA Oldridge, K Conkrite, KR Bosse, ... Journal of the National Cancer Institute 106 (4), dju047, 2014 | 106 | 2014 |
| Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features Q Liu, MR Russell, K Shahriari, DL Jernigan, MI Lioni, FU Garcia, ... Cancer research 73 (11), 3297-3305, 2013 | 106 | 2013 |
| Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in NeuroblastomaMEK1/2 and CDK4/6 Inhibitors Synergize against Neuroblastoma LS Hart, JA Rader, P Raman, V Batra, MR Russell, M Tsang, M Gagliardi, ... Clinical Cancer Research 23 (7), 1785-1796, 2017 | 64 | 2017 |
| Human Bone Marrow Activates the Akt Pathway in Metastatic Prostate Cells through Transactivation of the α-Platelet–Derived Growth Factor Receptor NG Dolloff, MR Russell, N Loizos, A Fatatis Cancer research 67 (2), 555-562, 2007 | 53 | 2007 |
| Targeting the α Receptor for Platelet-Derived Growth Factor as a Primary or Combination Therapy in a Preclinical Model of Prostate Cancer Skeletal MetastasisPDGFRα Inhibition … MR Russell, Q Liu, A Fatatis Clinical Cancer Research 16 (20), 5002-5010, 2010 | 52 | 2010 |
| The functional variant rs34330 of CDKN1B is associated with risk of neuroblastoma M Capasso, LD McDaniel, F Cimmino, A Cirino, D Formicola, MR Russell, ... Journal of Cellular and Molecular Medicine 21 (12), 3224-3230, 2017 | 46 | 2017 |
| The α-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells MR Russell, WL Jamieson, NG Dolloff, A Fatatis Oncogene 28 (3), 412-421, 2009 | 45 | 2009 |
| The α-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand-and dimerization-independent mechanisms MR Russell, Q Liu, H Lei, A Kazlauskas, A Fatatis Cancer research 70 (10), 4195-4203, 2010 | 23 | 2010 |
| TM (2001) A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport WR Oliver, SJL Snaith, MR Russell, CS Plunket, KD Bodkin, NL Lewis, ... Proc. Natl. Acad. Sci. USA 98, 5306-11, 0 | 14 | |
| Inhibition of checkpoint kinase 1 (Chk1) as a potential therapeutic for pediatric neuroblastoma MR Russell, KA Cole, JM Maris Cancer Research 71 (8_Supplement), 4758-4758, 2011 | 4 | 2011 |
| CDK4/CDK6 inhibition is potently active in a definable subset of human neuroblastomas. JA Rader, L Hart, M Russell, M Nakazawa, L Belcastro, D Martinez, ... Cancer Research 73 (8_Supplement), 2744-2744, 2013 | 3 | 2013 |
| The long intergenic noncoding RNA LINC00340 is a neuroblastoma susceptibility gene MR Russell, A Penikis, D Oldridge, M Diamond, S Diskin, J Maris, K Cole Cancer Research 74 (19_Supplement), 5237-5237, 2014 | 2 | 2014 |
| Therapeutic targeting of the DNA damage mediators CHK1 and Wee1 in neuroblastoma M Russell, K Levin, JA Rader, C Toniatti, JM Maris, KA Cole Cancer Research 72 (8_Supplement), 1436-1436, 2012 | 1 | 2012 |
| Endolyn contains lysosomal and apical targeting information in different domains of the protein G Ihrke, MRG Russell, JP Luzio MOLECULAR BIOLOGY OF THE CELL 11, 205A-205A, 2000 | 1 | 2000 |
| Abstract LB087: Characterization of JNJ-70218902, a TMEFF2 x CD3 bispecific antibody, in prostate cancer models S Basu, M Russell, K Sproesser, B Mattson, CL Lowenstein, ... Cancer Research 82 (12_Supplement), LB087-LB087, 2022 | | 2022 |
| Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer. MJ Morris, AO Sartor, JYC Wong, SI Max, H Xie, A Yu, CR Divgi, ... Journal of Clinical Oncology 40 (16_suppl), TPS5104-TPS5104, 2022 | | 2022 |
John M MarisProfessor Pediatrics, Children's Hospital of Philadelphia and University of PennsylvaniaVerified email at chop.edu
